β-amyloid binds to microglia Dectin-1 to induce inflammatory response in the pathogenesis of Alzheimer's disease

Xia Zhao1, Jinfeng Sun1,2, Li Xiong1

  • 1Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, 310012, China.

Insights

Dectin-1 on microglia drives Alzheimer's disease (AD) inflammation via beta-amyloid (Aβ) binding. Blocking Dectin-1 reduces Aβ-induced neuroinflammation and cognitive decline, offering a potential therapeutic target for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Microglia-mediated neuroinflammation is a key factor in Alzheimer's disease (AD) pathogenesis.
  • Pattern recognition receptors (PRRs) on microglia are crucial for sensing danger signals but their role in AD is not fully understood.

Purpose of the Study:

  • To investigate the role of Dectin-1, a pattern recognition receptor, in mediating microglial pro-inflammatory responses to beta-amyloid (Aβ) in Alzheimer's disease.
  • To elucidate the molecular mechanisms by which Dectin-1 contributes to AD pathology.

Main Methods:

  • Utilized Dectin-1 knockout AD mouse models infused with Aβ1-42 (Aβ42).
  • Employed BV2 cell models to study Aβ42-Dectin-1 interactions.
  • Investigated downstream signaling pathways including spleen tyrosine kinase (Syk) and nuclear factor-κB (NF-κB).

Main Results:

  • Dectin-1 knockout significantly reduced Aβ42-induced microglial activation and inflammatory responses in vivo and in vitro.
  • Cognitive deficits and synaptic impairments were ameliorated in Dectin-1 knockout AD mice.
  • Aβ42 directly binds to Dectin-1, triggering Dectin-1 homodimerization and activating the Syk/NF-κB pathway.

Conclusions:

  • Microglial Dectin-1 acts as a direct receptor for Aβ42, mediating pro-inflammatory responses and contributing to Alzheimer's disease pathology.
  • Targeting the Dectin-1-Aβ interaction presents a potential therapeutic strategy for neuroinflammation in AD.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220